News | May 29, 2022
JBCL rebrands as JB
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
The department will soon release a policy to catalyze research & development and innovation in the pharma- Medtech sector in India
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Subscribe To Our Newsletter & Stay Updated
